ImmunityBio Shares Rose After Turkish Expansion Talks
The biotech firm is targeting international growth as it seeks to establish a global cancer treatment hub.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Is news of a company's international meeting a good time for you to invest?
ImmunityBio shares gained 10 percent on Tuesday following a meeting between founder Patrick Soon-Shiong and Turkish President Recep Tayyip Erdogan regarding cancer treatment expansion. The company is leveraging $100 million in new capital to grow its footprint for its Anktiva therapy.
Why it matters
Investors signaled optimism as the firm pivots toward international markets, seeking to offset a $230.39 million net loss reported in the second quarter. The push to establish a hub in Turkey underscores a broader strategy to monetize the company's existing regulatory approvals across 34 countries.
ImmunityBio shares closed at $9.29 on Tuesday, a 10 percent increase amid $314.9 million in combined hedge fund holdings. The firm secured $100 million in funding through $75 million in non-dilutive financing from Oberland Capital and a $25 million debt conversion from Nant Capital.
The players
Patrick Soon-Shiong
The founder of ImmunityBio who is actively pursuing international expansion for the firm's cancer therapies.
Recep Tayyip Erdogan
The President of Turkey who met with company leadership to discuss potentially hosting a new cancer treatment hub.
ImmunityBio
A biotechnology company focused on immunotherapy with Anktiva regulatory approvals in 34 countries.
Oberland Capital
An investment firm that provided $75 million in non-dilutive financing to support the company's operations.
Nant Capital LLC
A private investment entity that completed a $25 million debt-conversion agreement with the company.
The details
The firm is utilizing a $75 million non-dilutive financing deal alongside a $25 million debt conversion to bolster its balance sheet as it attempts to scale its Anktiva rollout. This capital structure is intended to fuel international operations, which the company hopes will improve upon the $51.24 million in revenue recorded during the second quarter. The meeting with President Erdogan represents an effort to integrate the company's treatment model into Turkish infrastructure.
Timeline
ImmunityBio generated $51.24 million in revenue during Q2 2026.
The company's stock closed at $9.29 on September 29, 2026.
Market Landscape
This move follows the standard pattern of mid-stage biotechs leveraging existing regulatory approvals to secure liquidity during periods of high net losses. The strategy echoes broader industry trends where firms seek international partners to validate treatment protocols and broaden market access.
Operators should monitor whether the $100 million capital infusion provides sufficient runway to stabilize margins, given the company's significant second-quarter net loss. Businesses should also track how international hub developments influence supply chain and service requirements in the oncology space.
The takeaway
ImmunityBio is prioritizing international expansion as a critical path to financial stabilization after a challenging second quarter. Operators should watch how the firm’s non-dilutive financing agreements impact its debt-to-equity ratios in future filings.
Further reading
For more on industry shifts in oncology, see our Healthcare coverage.
Source note: This article includes information reported by RocketNews.
Live Poll
Is news of a company's international meeting a good time for you to invest?
